Kuznicki Law is investigating the proposed sale of F-star Therapeutics, Inc. (NasdaqCM: FSTX) to invoX Pharma. Under the terms of the proposed transaction, shareholders of F-star will receive only $7.12 in cash for each share of F-star that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
F-star Therapeutics, Inc. (NasdaqCM: FSTX) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.